27481907|t|Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease
27481907|a|To identify predictors of poor prognosis in patients with systemic sclerosis (SSc) associated with interstitial lung disease (ILD). Fifty patients with early-stage SSc - ILD who had never received disease - modifying drugs and were either observed for ≥ 10 years or died from ILD -related causes were enrolled. The baseline variables of patients who developed endstage lung disease (ESLD) were compared with those of patients who remained ESLD - free, and the Cox proportional hazard model was used to identify initial factors that correlated with ESLD development. Sixteen patients (32%) developed ESLD during 173.5 ± 64.7 months of followup. Elevated serum Krebs von den Lungen-6 (KL-6) at initial assessment was highly correlated with ESLD development (p = 0.0002). Receiver-operating characteristic curve analysis revealed that a KL-6 value of 1273 U/ml effectively discriminated patients who developed ESLD from those who did not. Patients with KL-6 > 1273 U/ml were less likely to remain ESLD - free compared with those with lower KL-6 levels (p < 0.0001). Multivariate analysis showed that KL-6 > 1273 U/ml was the most reliable predictor of ESLD development (OR 51.2, 95% CI 7.6-343, p < 0.0001). Finally, the initial KL-6 level correlated with the forced vital capacity (FVC) decline rate (r = 0.58, p < 0.0001). The natural course of SSc - ILD is highly variable. Baseline serum KL-6 is a biomarker potentially useful for predicting FVC decline.
27481907	0	8	Elevated	T080	C3163633
27481907	9	14	Serum	T031	C0229671
27481907	15	37	Krebs von den Lungen-6	T116,T129,T130	C1612111
27481907	41	46	Early	T079	C1279919
27481907	47	54	Disease	T047	C0012634
27481907	55	63	Predicts	T078	C0681842
27481907	64	74	Subsequent	T079	C0332282
27481907	75	88	Deterioration	T067	C0868945
27481907	92	110	Pulmonary Function	T042	C0231921
27481907	114	122	Patients	T101	C0030705
27481907	128	146	Systemic Sclerosis	T047	C0036421
27481907	151	176	Interstitial Lung Disease	T047	C0206062
27481907	189	199	predictors	T078	C2698872
27481907	208	217	prognosis	T058	C0033325
27481907	221	229	patients	T101	C0030705
27481907	235	253	systemic sclerosis	T047	C0036421
27481907	255	258	SSc	T047	C0036421
27481907	260	275	associated with	T080	C0332281
27481907	276	301	interstitial lung disease	T047	C0206062
27481907	303	306	ILD	T047	C0206062
27481907	315	323	patients	T101	C0030705
27481907	329	340	early-stage	T079	C2363430
27481907	341	344	SSc	T047	C0036421
27481907	347	350	ILD	T047	C0206062
27481907	374	381	disease	T047	C0012634
27481907	384	393	modifying	T169	C0392747
27481907	394	399	drugs	T121	C0013227
27481907	434	439	years	T079	C0439234
27481907	443	447	died	T040	C0011065
27481907	453	456	ILD	T047	C0206062
27481907	466	472	causes	T033	C0007465
27481907	492	500	baseline	T081	C1442488
27481907	501	510	variables	T080	C0439828
27481907	514	522	patients	T101	C0030705
27481907	527	536	developed	T169	C1527148
27481907	537	558	endstage lung disease	T047	C0024115
27481907	560	564	ESLD	T047	C0024115
27481907	594	602	patients	T101	C0030705
27481907	616	620	ESLD	T047	C0024115
27481907	623	627	free	T169	C0332296
27481907	637	666	Cox proportional hazard model	T081,T170	C0033489
27481907	688	695	initial	T079	C0205265
27481907	696	703	factors	T169	C1521761
27481907	709	719	correlated	T080	C1707520
27481907	725	729	ESLD	T047	C0024115
27481907	730	741	development	T169	C1527148
27481907	751	759	patients	T101	C0030705
27481907	766	775	developed	T169	C1527148
27481907	776	780	ESLD	T047	C0024115
27481907	801	807	months	T079	C0439231
27481907	811	819	followup	T058	C1522577
27481907	821	829	Elevated	T080	C3163633
27481907	830	835	serum	T031	C0229671
27481907	836	858	Krebs von den Lungen-6	T116,T129,T130	C1612111
27481907	860	864	KL-6	T116,T129,T130	C1612111
27481907	869	876	initial	T079	C0205265
27481907	877	887	assessment	T058	C0184514
27481907	899	909	correlated	T080	C1707520
27481907	915	919	ESLD	T047	C0024115
27481907	920	931	development	T169	C1527148
27481907	946	994	Receiver-operating characteristic curve analysis	T062	C0936012
27481907	995	1003	revealed	T080	C0443289
27481907	1011	1015	KL-6	T116,T129,T130	C1612111
27481907	1047	1060	discriminated	T080	C0205235
27481907	1061	1069	patients	T101	C0030705
27481907	1074	1083	developed	T169	C1527148
27481907	1084	1088	ESLD	T047	C0024115
27481907	1113	1121	Patients	T101	C0030705
27481907	1127	1131	KL-6	T116,T129,T130	C1612111
27481907	1171	1175	ESLD	T047	C0024115
27481907	1178	1182	free	T169	C0332296
27481907	1183	1191	compared	T052	C1707455
27481907	1214	1218	KL-6	T116,T129,T130	C1612111
27481907	1219	1225	levels	T080	C0441889
27481907	1240	1261	Multivariate analysis	T081	C0026777
27481907	1274	1278	KL-6	T116,T129,T130	C1612111
27481907	1313	1322	predictor	T078	C2698872
27481907	1326	1330	ESLD	T047	C0024115
27481907	1331	1342	development	T169	C1527148
27481907	1344	1346	OR	T081	C0028873
27481907	1357	1359	CI	T081	C0009667
27481907	1395	1402	initial	T079	C0205265
27481907	1403	1407	KL-6	T116,T129,T130	C1612111
27481907	1408	1413	level	T080	C0441889
27481907	1414	1424	correlated	T080	C1707520
27481907	1434	1455	forced vital capacity	T033	C0580371
27481907	1457	1460	FVC	T033	C0580371
27481907	1462	1469	decline	T081	C0547047
27481907	1470	1474	rate	T081	C1521828
27481907	1511	1517	course	T079	C0750729
27481907	1521	1524	SSc	T047	C0036421
27481907	1527	1530	ILD	T047	C0206062
27481907	1534	1540	highly	T080	C0205250
27481907	1541	1549	variable	T080	C0439828
27481907	1551	1559	Baseline	T081	C1442488
27481907	1560	1565	serum	T031	C0229671
27481907	1566	1570	KL-6	T116,T129,T130	C1612111
27481907	1576	1585	biomarker	T201	C0005516
27481907	1609	1619	predicting	T078	C0681842
27481907	1620	1623	FVC	T033	C0580371
27481907	1624	1631	decline	T081	C0547047